Discontinuation of anti-PD-1 monotherapy in advanced melanoma: outcomes of daily clinical practice
- Zeijl, M.C.T. van
- Eertwegh, A.J.M. van den
- Wouters, M.W.J.M.
- Wreede, L.C. de
- Aarts, M.J.B.
- Berkmortel, F.W.P.J. van den
- Groot, J.W.B. de
- Hospers, G.A.P.
- Kapiteijn, E.
- Piersma, D.
- Rijn, R.S. van
- Suijkerbuijk, K.P.M.
- Tije, A.J. ten
- Veldt, A.A.M. van der
- Vreugdenhil, G.
- Hoeven, J.J.M. van der
- Haanen, J.B.A.G.
DOIAbstract
There is no consensus on the optimal treatment duration of anti-PD-1 for advanced melanoma. The aim of our study was to gain insight into the outcomes of anti-PD-1 discontinuation, the association of treatment duration with progression and anti-PD-1 re-treatment in relapsing patients. Analyses were performed on advanced melanoma patients in the Netherlands who discontinued first-line anti-PD-1 monotherapy in the absence of progressive disease (n = 324). Survival was estimated after anti-PD-1 discontinuation and with a Cox model the association of treatment duration with progression was assessed. At the time of anti-PD-1 discontinuation, 90 (28%) patients had a complete response (CR), 190 (59%) a partial response (PR) and 44 (14%) stable dis...
Add to ORKG